Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1376481 | Bioorganic & Medicinal Chemistry Letters | 2006 | 5 Pages |
Abstract
A series of PPARδ-selective agonists was investigated and optimized for a favorable in vivo pharmacokinetic profile. Isoxazole LCI765 (17d) was found to be a potent and selective PPARδ agonist with good in vivo PK properties in mouse (Cmax = 5.1 μM, t1/2 = 3.1 h). LCI765 regulated expression of genes involved in energy homeostasis in relevant tissues when dosed orally in C57BL6 mice. A co-crystal structure of compound LCI765 and the LBD of PPARδ is discussed.
Graphical abstractThe optimization of an isoxazole series to the potent, selective, and bioavailable PPARδ agonist LCI765 is reported. A co-crystal structure and in vivo properties of LCI765 are discussed.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Robert Epple, Mihai Azimioara, Ross Russo, Yongping Xie, Xing Wang, Christopher Cow, John Wityak, Don Karanewsky, Badry Bursulaya, Andreas Kreusch, Tove Tuntland, Andrea Gerken, Maya Iskandar, Enrique Saez, H. Martin Seidel, Shin-Shay Tian,